Man Group’s Intellia Therapeutics NTLA Stock Holding History

Man Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-53,795	Closed	-$690K	–	2526
2026 Q1	$690K	Buy	53,795 +40,336	+300%	+$514K	﹤0.01%	1966
2025 Q4	$121K	Buy	+13,459	New	+$185K	﹤0.01%	2176
2024 Q2	–	Sell	-47,986	Closed	-$1.32M	–	2194
2024 Q1	$1.32M	Sell	47,986 -146,119	-75%	-$4.06M	﹤0.01%	1451
2023 Q4	$5.92M	Buy	+194,105	New	+$5.58M	0.02%	873
2023 Q3	–	Hold	0	–	–	–	1450
2023 Q1	–	Sell	-30,465	Closed	-$1.06M	–	2190
2022 Q4	$1.06M	Buy	30,465 +8,611	+39%	+$409K	﹤0.01%	1302
2022 Q3	$1.22M	Buy	+21,854	New	+$1.36M	0.01%	1220
2018 Q4	–	Sell	-32,400	Closed	-$927K	–	2055
2018 Q3	$927K	Sell	32,400 -65,900	-67%	-$1.92M	﹤0.01%	1694
2018 Q2	$2.69M	Sell	98,300 -43,200	-31%	-$1.05M	0.01%	1246
2018 Q1	$2.98M	Buy	+141,500	New	+$3.48M	0.01%	1113

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Man Group's NTLA Position: Q2 2026 in Review

Man Group sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 53,795 shares — an estimated $690K sold.

Man Group first reported a position in NTLA in Q1 2018 and held it in 9 quarters. The position peaked at $5.92M in Q4 2023. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Man Group reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
Man Group sold 53,795 Intellia Therapeutics shares in Q2 2026, an estimated $690K.
Man Group first reported a position in Intellia Therapeutics in Q1 2018 and held it in 9 quarters.
Man Group's Intellia Therapeutics position peaked at $5.92M in Q4 2023.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.